Literature DB >> 34532551

In vitro Membrane Interaction and Liposome Fusion Assays Using Recombinant Hepatitis C Virus Envelope Protein E2.

Belén Yélamos1, Mar Rodríguez-Rodríguez1, Francisco Gavilanes1, Julián Gómez-Gutiérrez1.   

Abstract

In order to study the mechanism underlying the Hepatitis C Virus (HCV) fusion process we have performed assays using phospholipid liposomes and a truncated form of E2 protein, E2661 (amino acids 384-661 of the HCV polyprotein) lacking the transmembrane region. E2661 has been previously generated by using the baculovirus expression system. This form has been used in lipid-protein interaction studies with different model vesicles at different pHs, and monitored using a variety of fluorescent assays. After the analysis of the results, we observed that E2661 is able to insert into lipid bilayers and to induce vesicle aggregation, lipid mixing and liposome leakage, showing higher values of membrane destabilization for negatively charged phospholipids at acidic pH. This is indicative of the role of E2 glycoprotein in the HCV initial infective steps, interacting with the target membranes and producing their destabilization.
Copyright © 2018 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Aggregation; Envelope proteins E1 and E2; Fusion; Hepatitis C virus; Leakage; Lipid mixing; Phospholipid vesicles

Year:  2018        PMID: 34532551      PMCID: PMC8342114          DOI: 10.21769/BioProtoc.3108

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  12 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Fusogenic properties of the Ectodomain of HCV E2 envelope protein.

Authors:  Mar Rodríguez-Rodríguez; Daniel Tello; Julián Gómez-Gutiérrez; Darrell L Peterson; Francisco Gavilanes; Belén Yélamos
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-12-20       Impact factor: 3.747

3.  Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.

Authors:  George Koutsoudakis; Artur Kaul; Eike Steinmann; Stephanie Kallis; Volker Lohmann; Thomas Pietschmann; Ralf Bartenschlager
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes.

Authors:  Dimitri Lavillette; Birke Bartosch; Delphine Nourrisson; Géraldine Verney; François-Loïc Cosset; François Penin; Eve-Isabelle Pécheur
Journal:  J Biol Chem       Date:  2005-12-15       Impact factor: 5.157

5.  Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles.

Authors:  Laurent Meertens; Claire Bertaux; Tatjana Dragic
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

6.  Fluorescence depolarization studies of phase transitions and fluidity in phospholipid bilayers. 2 Two-component phosphatidylcholine liposomes.

Authors:  B R Lentz; Y Barenholz; T E Thompson
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

7.  Use of resonance energy transfer to monitor membrane fusion.

Authors:  D K Struck; D Hoekstra; R E Pagano
Journal:  Biochemistry       Date:  1981-07-07       Impact factor: 3.162

8.  H+- and Ca2+-induced fusion and destabilization of liposomes.

Authors:  H Ellens; J Bentz; F C Szoka
Journal:  Biochemistry       Date:  1985-06-18       Impact factor: 3.162

9.  Structural properties of the ectodomain of hepatitis C virus E2 envelope protein.

Authors:  Mar Rodríguez-Rodríguez; Daniel Tello; Belén Yélamos; Julián Gómez-Gutiérrez; Beatriz Pacheco; Sara Ortega; Alicia G Serrano; Darrell L Peterson; Francisco Gavilanes
Journal:  Virus Res       Date:  2008-12-06       Impact factor: 3.303

10.  The CD81 partner EWI-2wint inhibits hepatitis C virus entry.

Authors:  Vera Rocha-Perugini; Claire Montpellier; David Delgrange; Czeslaw Wychowski; François Helle; André Pillez; Hervé Drobecq; François Le Naour; Stéphanie Charrin; Shoshana Levy; Eric Rubinstein; Jean Dubuisson; Laurence Cocquerel
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.